Grant Pickering, Vaxcyte CEO
September 3, 2024 07:42 AM EDTUpdated 10:07 AM
R&D

Up­dat­ed: Vax­cyte surges on Phase 1/2 da­ta for 31-va­lent pneu­mo­coc­cal vac­cine

Max Gelman

Senior Editor

Vax­cyte shares $PCVX jumped more than 40% Tues­day morn­ing on the heels of Phase 1/2 da­ta for its 31-va­lent pneu­mo­coc­cal con­ju­gate vac­cine, VAX-31, be­ing test­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times